Compare ICHR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | CRVS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.5M | 546.7M |
| IPO Year | 2016 | 2016 |
| Metric | ICHR | CRVS |
|---|---|---|
| Price | $29.78 | $8.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $27.50 | $13.75 |
| AVG Volume (30 Days) | 795.7K | ★ 1.6M |
| Earning Date | 02-09-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $957,337,000.00 | N/A |
| Revenue This Year | $13.48 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.86 | N/A |
| 52 Week Low | $13.12 | $2.54 |
| 52 Week High | $35.56 | $9.60 |
| Indicator | ICHR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 84.60 | 58.46 |
| Support Level | $21.44 | $6.46 |
| Resistance Level | $31.43 | $7.18 |
| Average True Range (ATR) | 1.77 | 0.50 |
| MACD | 0.90 | 0.08 |
| Stochastic Oscillator | 87.41 | 93.26 |
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).